Aphoenix

Aphoenix is a San Francisco-based biotechnology company dedicated to discovering and developing next-generation small molecule therapeutics for cancer. Founded by pioneers in chemical biology and functional genomics from the University of California, San Francisco (UCSF), the company utilizes a proprietary platform that combines CRISPR-based screening with chemical proteomics to identify novel, druggable vulnerabilities in tumor cells. Aphoenix focuses on targets that have traditionally been considered undruggable, aiming to provide new treatment options for patients with hard-to-treat malignancies. The company's approach integrates high-throughput functional genomics with deep mechanistic insights to overcome drug resistance and identify synthetic lethal interactions. Aphoenix is backed by prominent life science investors and is currently advancing its discovery-stage pipeline toward clinical development.